CAMP4 Therapeutics Corporation (CAMP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.13 |
| Open | 4.08 |
| Day High | 4.3 |
| Day Low | 3.98 |
| 52-Week High | 7.75 |
| 52-Week Low | 1.32 |
| Volume | 116,072 |
| Average Volume | 95,306 |
| Market Cap | 89.21M |
| PE | -1.77 |
| EPS | -2.37 |
| Moving Average 50 Days | 4.3 |
| Moving Average 200 Days | 4.25 |
| Change | 0.07 |
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Dec 18, 2025 12:10 PM GMT
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments,